ENCell Co Ltd
456070
Company Profile
Business description
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.
Contact
701 Yeongdong-daero
11th floor
Gangnam-gu
Seoul
KORT: +82 262058050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
112
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,005.40 | 121.80 | -1.33% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,329.99 | 166.56 | -0.65% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,920.28 | 390.21 | -0.92% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,733.90 | 125.10 | -1.41% |
| SSE Composite Index | 3,812.75 | 45.39 | -1.18% |